SpringWorks Therapeutics Inc Ordinary Shares SWTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN
-
SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
-
SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors
-
SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
-
Kuehn Law Encourages Investors of SpringWorks, Therapeutics Inc. to Contact Law Firm
-
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
-
SpringWorks stock on track for record gain after FDA approves first treatment for rare type of aggressive tumors
-
SpringWorks Shares Rise on FDA Approval for Tumor Treatment
Trading Information
- Previous Close Price
- $32.29
- Day Range
- $32.24–33.29
- 52-Week Range
- $18.00–53.92
- Bid/Ask
- $32.11 / $32.26
- Market Cap
- $2.40 Bil
- Volume/Avg
- 603,629 / 880,069
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 25.81
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 305
- Website
- https://www.springworkstx.com
Comparables
Valuation
|
Metric
|
SWTX
|
PTCT
|
OMER
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.31 | — | — |
Price/Sales | 25.81 | 3.17 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
SWTX
PTCT
OMER
Financial Strength
|
Metric
|
SWTX
|
PTCT
|
OMER
|
|---|---|---|---|
Quick Ratio | 7.49 | 2.10 | 3.31 |
Current Ratio | 7.91 | 2.23 | 3.41 |
Interest Coverage | — | −2.15 | −5.61 |
Quick Ratio
SWTX
PTCT
OMER
Profitability
|
Metric
|
SWTX
|
PTCT
|
OMER
|
|---|---|---|---|
Return on Assets (Normalized) | −32.86% | −15.67% | −43.94% |
Return on Equity (Normalized) | −37.78% | — | — |
Return on Invested Capital (Normalized) | −42.13% | −102.66% | −75.82% |
Return on Assets
SWTX
PTCT
OMER
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Nfzrlmqvfc | Sdtgp | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Htzmxrxjq | Vnrjpj | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Hnnmkthtg | Jkqzwqq | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Yfglrzg | Pspdwg | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Drcywcyh | Vvxs | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Hbsxvxy | Ykxpv | $28.1 Bil | |||
| Moderna Inc
MRNA
| Mxtcbnknj | Vwdw | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Hqrqdwrt | Tjxb | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Xbplkphl | Xgsrnb | $13.4 Bil | |||
| Incyte Corp
INCY
| Brvnqqx | Jhycmf | $12.7 Bil |
United States